iRhythm Technologies Reports 26% Revenue Growth to $199.4 Million in Q1 2026

iRhythm Technologies, Inc. reported a significant increase in financial performance for the first quarter of 2026, with net revenue reaching $199.4 million, a 26% increase from $158.7 million in the same period last year. The growth was primarily driven by a higher volume of iRhythm Services, particularly from existing and new accounts within third-party payors, the Centers for Medicare & Medicaid Services (CMS), and healthcare institutions. The company also noted improvements in contractual allowance reserves, which contributed to a modest increase in average selling prices.

Despite the revenue growth, iRhythm's cost of revenue also rose, increasing by 17% to $58.0 million, attributed to higher material component costs, labor expenses, and freight costs associated with increased service volume. However, the company managed to improve its gross profit margin, which increased by 29% to $141.4 million. Operating expenses rose to $157.5 million, up 11% from the previous year, largely due to increased legal and professional fees related to ongoing litigation, as well as provisions for credit losses.

The company reported a net loss of $13.9 million for the quarter, a 55% improvement compared to a net loss of $30.7 million in the first quarter of 2025. This reduction in losses was attributed to the increase in revenue and operational efficiencies. iRhythm's Adjusted EBITDA for the quarter was $14.1 million, a notable turnaround from a loss of $2.6 million in the prior year, indicating improved operational performance.

In terms of strategic developments, iRhythm completed a corporate restructuring in January 2026, forming a new parent holding company. This restructuring did not affect the company's operational capabilities or financial position. The company continues to focus on expanding its market presence, particularly in the U.S., where it generates the majority of its revenue. As of March 31, 2026, iRhythm had cash and cash equivalents of $240.1 million and marketable securities of $309.5 million, providing a solid liquidity position to support ongoing operations and growth initiatives.

Looking ahead, iRhythm Technologies anticipates continued growth driven by increased demand for its ambulatory cardiac monitoring services. However, the company remains cautious about potential macroeconomic challenges, including inflation and supply chain disruptions, which could impact its operations and financial results. The management is committed to navigating these challenges while focusing on enhancing its product offerings and expanding its customer base.